Abstract 4317
Background
Adenocarcinoma of esophagogastric junction (AEG) is a special type of malignant tumor which occurs in the upper gastrointestinal tract. However, AEG is different from esophageal or gastric cancer. Its biological behavior is complicated and prognosis is poor. Even after radical resection, the overall 5-year survival rate is still very low. An in-depth analysis of the prognostic factors in patients with AEG may indicate a certain direction for clinical treatment and decision-making as well as for improving the prognosis of patients with AEG. Although some researchers have explored the factors influencing the prognosis of AEG, the independent prognostic factors are still unclear, which need to be further studied.
Methods
The clinical data of patients with AEG who underwent surgical treatment in PLA general hospital from January 2009 to January 2013 were collected retrospectively. According to the inclusion and exclusion criteria, a total of 343 patients with AEG were included in the study. Sex, age, basic disease, Siewert classification, tumor size (Diameter), differentiation, vascular cancer thrombus, nerve invasion, T-stage,N stage, pTNM, approach, minimally invasive surgery, resection scope, adjuvant chemotherapy, HER-2 and Ki-67 expression were analyzed comprehensively to study the independent or nonindependent prognostic factors in patients with AEG.
Results
The median follow-up time of the 343 patients with AEG was 50.2 months. The 5-year overall survival rate of the whole group (no IV stage) was 49.2%. Univariate analysis showed that age, basic disease, Siewert classification, tumor size (Diameter), differentiation, vascular cancer thrombus, nerve invasion, T-stage,N stage, pTNM, adjuvant chemotherapy, level of Ki-67 expression was correlated with prognosis (P < 0 05). Multivariate analysis showed that age, tumor size(Diameter), differentiation, pTNM and adjuvant chemotherapy were independent prognostic factors affecting the overall survival of the patients (P < 0 05).
Conclusions
The age, tumor size (Diameter), differentiation degree, pTNM and adjuvant chemotherapy were independent prognostic factors affecting the overall survival rate of patients with AEG (P < 0 05).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wangxinxin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3875 - Correlation of radiotherapy with the prognosis of elderly patients with hormone receptor-positive breast cancer according to immunohistochemical subtyping
Presenter: Jin Zhang
Session: Poster Display session 2
Resources:
Abstract
5793 - Real world treatment sequencing patterns in secondary breast cancer (SBC): Pathway visualisation using national datasets.
Presenter: Ashley Horne
Session: Poster Display session 2
Resources:
Abstract
3185 - Utilization Pattern of Bone Targeting Agents in Patients with Solid Tumor in Taiwan, Hong Kong and Korea
Presenter: Shi Jie Lai
Session: Poster Display session 2
Resources:
Abstract
3705 - Clinico-pathological Features and Prognosis of Patients with Pregnancy Associated Breast Cancer – A Matched Case Control Study
Presenter: Ruyan Zhang
Session: Poster Display session 2
Resources:
Abstract
1421 - TRYbeCA-2: A Randomized Phase 2/3 Study of Eryaspase in Combination with Gemcitabine and Carboplatin Chemotherapy versus Chemotherapy Alone As First-Line Treatment in Patients with Metastatic or Locally Recurrent Triple-Negative Breast Cancer
Presenter: Ahmad Awada
Session: Poster Display session 2
Resources:
Abstract
4119 - CONTESSA TRIO: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus 3 Different PD-(L)1 Inhibitors in Patients with Metastatic Triple-Negative Breast Cancer (TNBC) and Tesetaxel Monotherapy in Elderly Patients with HER2- Metastatic Breast Cancer (MBC)
Presenter: Sara Tolaney
Session: Poster Display session 2
Resources:
Abstract
4545 - Bintrafusp alfa (M7824) and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer (TNBC)(NCT03579472)
Presenter: Jennifer Litton
Session: Poster Display session 2
Resources:
Abstract
3340 - Effectiveness of Olaparib Plus Trastuzumab in HER2[+], BRCA–mutated (BRCAm) or Homologous Recombination Deficient (HRD) Advanced Breast Cancer (ABC) patients (pts). The OPHELIA Study
Presenter: José Enrique Alés-Martínez
Session: Poster Display session 2
Resources:
Abstract
1113 - RIBOB : A Study on the efficacy and safety of Ribociclib in combination with letrozole in Older women (≥70 years) with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced Breast cancer (aBC) with no prior systemic therapy for advanced disease
Presenter: Cindy Kenis
Session: Poster Display session 2
Resources:
Abstract
4025 - RIbociclib plus Goserelin with Hormonal Therapy versus physician Choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2– inoperable locally advanced or metastatic breast cancer – RIGHT Choice study
Presenter: Nagi El Saghir
Session: Poster Display session 2
Resources:
Abstract